YH011 is an antibody-cytokine fusion protein at discovery stage. We have licensed our humanized PD-L1 monoclonal antibody to GeneQuantum for the co-development of YH011 PD-L1 x cytokine bifunctional molecule.

PD-L1

PD-L1 is expressed on tumor cells and bind to PD-1 on T cells to initiates the programmed death of T cells. This down-regulates the immune system, reducing T cell activity and leading to immune escape of tumor cells. PD-L1 immunosuppressants function to block the inhibitory binding of tumor cells to T cells, enabling T cells to continuously recognize and eliminate tumor cells.